Could Affimed Be a Millionaire-Maker Stock?
Shares of Affimed (NASDAQ: AFMD) have been soaring on the back of positive clinical trial results for an experimental cancer therapy that could be worth billions. The stock has already gained around 61% this year, but some biotech investors think it could climb much higher. Can Affimed really make a millionaire out of the average investor?